Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 2/20 | 0.33 |
| ▸ | PLG | P00747 | 1/20 | 0.32 |
| ▸ | PLAT | P00750 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | KDM5A | P29375 | 1/20 | 0.31 |
| ▸ | KDM7A | Q6ZMT4 | 1/20 | 0.31 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.31 |
| ▸ | PHF8 | Q9UPP1 | 1/20 | 0.31 |
| ▸ | KDM2A | Q9Y2K7 | 1/20 | 0.31 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.30 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.30 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4877014 | 1.00 | HSD11B1 (0.33) | HSD11B1PLGPLATLMNAKDM5A | |
| SCHEMBL2334916 | 0.88 | PLG (0.46) | HSD11B1PLGPLATLMNA | |
| SCHEMBL2334920 | 0.88 | PLG (0.46) | HSD11B1PLGPLATLMNA | |
| Hydrochloric Acid SCHEMBL4473664 | 0.86 | PLG (0.44) | HSD11B1PLGPLATLMNA | |
| Hydrochloric Acid SCHEMBL4473661 | 0.86 | PLG (0.44) | HSD11B1PLGPLATLMNA | |
| SCHEMBL705608 | 0.84 | KDM5A (0.32) | HSD11B1KDM5AKDM7AKDM4CPHF8 | |
| SCHEMBL705607 | 0.84 | KDM5A (0.32) | HSD11B1KDM5AKDM7AKDM4CPHF8 | |
| SCHEMBL527479 | 0.83 | DPP4 (0.30) | — | |
| SCHEMBL2167298 | 0.83 | KDM5A (0.31) | HSD11B1KDM5AKDM7AKDM4CPHF8 | |
| SCHEMBL2167294 | 0.83 | KDM5A (0.31) | HSD11B1KDM5AKDM7AKDM4CPHF8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9067937-B2 | 1,5-naphthyridine derivatives and MELK inhibitors containing the same | ONCOTHERAPY SCIENCE, INC. (JP) | 2015-06-30 | — | — | US | disclosed |
| US-20150005302-A1 | 1,5-NAPHTHYRIDINE DERIVATIVES AND MELK INHIBITORS CONTAINING THE SAME | ONCOTHERAPY SCIENCE, INC. (JP) | 2015-01-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150005302-A1 | 1,5-NAPHTHYRIDINE DERIVATIVES AND MELK INHIBITORS CONTAINING THE SAME | MELK, NEK1, NEK5 | HSD11B1 3690/4885PLG 2450/4885PLAT 1880/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.